Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $160.00 at Guggenheim

Apogee Therapeutics (NASDAQ:APGE) had its target price upped by equities research analysts at Guggenheim from $130.00 to $160.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price objective indicates a potential upside of 101.92% from the company’s previous close.

Several other equities analysts have also issued reports on APGE. Wall Street Zen lowered shares of Apogee Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Stifel Nicolaus set a $133.00 price target on Apogee Therapeutics in a research note on Tuesday, January 6th. Royal Bank Of Canada lowered their price objective on Apogee Therapeutics from $83.00 to $82.00 and set a “sector perform” rating for the company in a research note on Monday, March 2nd. Wolfe Research started coverage on Apogee Therapeutics in a report on Wednesday, January 7th. They issued a “peer perform” rating on the stock. Finally, Craig Hallum reissued a “buy” rating and issued a $116.00 target price on shares of Apogee Therapeutics in a research note on Wednesday, January 7th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $107.58.

Apogee Therapeutics Price Performance

Shares of Apogee Therapeutics stock opened at $79.24 on Tuesday. The company has a 50-day moving average of $71.28 and a 200 day moving average of $63.70. The firm has a market cap of $5.51 billion, a price-to-earnings ratio of -18.78 and a beta of 1.39. Apogee Therapeutics has a 1 year low of $26.20 and a 1 year high of $84.56.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.02. On average, equities analysts anticipate that Apogee Therapeutics will post -3.09 EPS for the current year.

Insider Buying and Selling

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $74.78, for a total value of $1,495,600.00. Following the completion of the transaction, the chief executive officer owned 1,152,987 shares of the company’s stock, valued at approximately $86,220,367.86. The trade was a 1.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Fairmount Funds Management Llc sold 1,750,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total transaction of $133,525,000.00. Following the transaction, the director owned 298,647 shares in the company, valued at $22,786,766.10. This represents a 85.42% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 1,839,700 shares of company stock worth $140,118,083. 42.77% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Exane Asset Management purchased a new stake in Apogee Therapeutics during the 3rd quarter valued at $2,048,000. JPMorgan Chase & Co. lifted its holdings in shares of Apogee Therapeutics by 57.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,137,731 shares of the company’s stock valued at $45,202,000 after buying an additional 417,161 shares during the period. Rafferty Asset Management LLC boosted its stake in shares of Apogee Therapeutics by 55.9% in the 3rd quarter. Rafferty Asset Management LLC now owns 65,796 shares of the company’s stock worth $2,614,000 after buying an additional 23,585 shares during the last quarter. Boxer Capital Management LLC bought a new stake in shares of Apogee Therapeutics in the third quarter worth $1,986,000. Finally, SG Americas Securities LLC bought a new stake in shares of Apogee Therapeutics in the third quarter worth $5,333,000. Institutional investors own 79.04% of the company’s stock.

Trending Headlines about Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: APEX Part A 52‑week data showed durable maintenance of response with Q3M and Q6M dosing — 75% and 85% maintained EASI‑75; high rates on vIGA 0/1 and improvements in itch and lesion endpoints. This is the primary catalyst for the rally as it validates long‑duration dosing and clinical durability. GlobeNewswire APEX Part A Data
• Positive Sentiment: Press coverage and summaries emphasize durable efficacy with infrequent dosing (every 3 or 6 months), a potential compliance and commercial advantage versus more frequent biologics — a structural benefit that could support market adoption. Benzinga Article
• Positive Sentiment: BTIG reaffirmed a Buy and set a $137 price target, and independent analysis on Seeking Alpha reiterates a Buy thesis citing strong Phase 2 data, Q3M/Q6M dosing advantage, and a healthy cash position — these endorsements bolster investor confidence. Seeking Alpha Buy Thesis
• Neutral Sentiment: Apogee hosted a conference call/webcast to review the 52‑week data — useful for detail and Q&A but not an independent catalyst beyond the press release. Conference Call Notice
• Neutral Sentiment: Short interest data reported is anomalous/zero and not informative for current market dynamics (does not explain intraday moves). Investors should treat reported short‑interest figures with caution.
• Negative Sentiment: Apogee announced a proposed $300M underwritten public offering (plus a 30‑day option for up to $45M), which is dilutive and can cap near‑term upside as the market digests potential share issuance. The offering proceeds likely support late‑stage development but increase supply risk. GlobeNewswire Offering

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.